Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980157 | 0.95 | NR3C1 (0.33) | NR3C1PGRNR3C2ALDH1A1MAOA | |
| SCHEMBL2757073 | 0.88 | CYP1A2 (0.39) | NR3C1PGRCYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL2705610 | 0.88 | NR1I2 (0.37) | NR3C1PGRNR3C2ALDH1A1AAK1 | |
| SCHEMBL15463301 | 0.84 | CYP1A2 (0.35) | CYP1A2CYP2A6MAOAMAOB | |
| SCHEMBL9980110 | 0.82 | CYP1A2 (0.32) | CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL15368412 | 0.81 | GAA (0.33) | CYP1A2CYP2A6ALDH1A1MAOAMAOB | |
| SCHEMBL9980296 | 0.81 | MEN1 (0.37) | NR3C1PGRCYP1A2CYP2A6MAOA | |
| SCHEMBL12676884 | 0.78 | AAK1 (0.32) | ALDH1A1AAK1 | |
| SCHEMBL9980215 | 0.78 | CYP1A2 (0.39) | CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL9980105 | 0.78 | CYP1A2 (0.37) | CYP1A2CYP2A6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR3C1 3925/4885PGR 4048/4885NR3C2 4498/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR3C1 3925/4885PGR 4048/4885NR3C2 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.